Consensus statement on the use of clozapine during the COVID-19 pandemic
Date
2020Journal
Journal of psychiatry & neuroscience : JPNPublisher
Canadian Medical AssociationType
Article
Metadata
Show full item recordAbstract
With the ongoing coronavirus disease 2019 (COVID-19) pandemic, psychiatrists find themselves in the clinical situation of being asked by patients, family members and patient advocacy societies to help ensure access to clozapine as a medication critical for ongoing patient care. To provide clozapine prescribing guidance and facilitate regulatory agencies modifying laboratory monitoring and/or dispensing requirements, an expert advisory subgroup of the Treatment Response and Resistance in Psychosis working group developed the following background, recommendations and rationale as a consensus statement.
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083188654&doi=10.1503%2fjpn.200061&partnerID=40&md5=0dc3ecc0fb112ea187d0e82342f634e5; http://hdl.handle.net/10713/12640ae974a485f413a2113503eed53cd6c53
10.1503/jpn.200061
Scopus Count
Related articles
- Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.
- Authors: Berk M, Fitzsimons J, Lambert T, Pantelis C, Kulkarni J, Castle D, Ryan EW, Jespersen S, McGorry P, Berger G, Kuluris B, Callaly T, Dodd S
- Issue date: 2007
- Clozapine--a perspective. Accepted as a consensus statement by the ACNP Council, August 13, 1990.
- Authors: Shader RI
- Issue date: 1991 Feb
- The disquietude of clozapine continuation during the COVID-19 pandemic.
- Authors: Shoib S, Bharati-Sinha V, Javed S, Gürcan A, Gürcan G, Das S, Chandradasa M, Saeed F
- Issue date: 2022 Mar
- Clozapine and COVID-19.
- Authors: Silva E, Gee S, Smith S, Gaughran F
- Issue date: 2020 Aug